CoChat

Fatty Acid Synthase Inhibitor TVB‐2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

Syed‐Abdul, Majid M., Parks, Elizabeth J., Gaballah, Ayman H., Bingham, Kimberlee, Hammoud, Ghassan M., Kemble, George, Buckley, Douglas, McCulloch, William, Manrique-Acevedo, Camila · 2020 · Hepatology
Cited by 130

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Background and Aims: Elevated hepatic de novo lipogenesis (DNL) is a key distinguishing characteristic of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis. In rodent models of NAFLD, treatment with a surrogate of TVB‐2640, a pharmacological fatty acid synthase inhibitor, has been shown to reduce hepatic fat and other biomarkers of DNL. The purpose of this phase I clinical study was to test the effect of the TVB‐2640 in obese men with certain metabolic abnormalities that put them at risk for NAFLD. Approach and Results: Twelve subjects (mean ± SEM, 42 ± 2 years, body mass index 37.4 ± 1.2 kg/m 2, glucose 103 ± 2 mg/dL, triacylglycerols 196 ± 27 mg/dL, and elevated liver enzymes) underwent 10 days of treatment with TVB‐2640 at doses ranging from 50‐150 mg/day. Food intake was controlled throughout the study. Hepatic DNL was measured before and after an oral fructose/glucose bolus using isotopic labeling with 1‐13 C 1‐acetate intravenous infusion, followed by measurement of labeled very low‐density lipoprotein palmitate via gas chromatography mass spectometry. Substrate oxidation was measured by indirect calorimetry. Across the range of doses, fasting DNL was reduced by up to 90% (P = 0.003). Increasing plasma concentrations of TVB‐2640 were associated with progressive reductions in the percent of fructose‐stimulated peak fractional DNL (R 2 = −0.749, P = 0.0003) and absolute DNL area under the curve 6 hours following fructose/glucose bolus (R 2 = −0.554, P = 0.005). For all subjects combined, alanine aminotransferase was reduced by 15.8 ± 8.4% (P = 0.05). Substrate oxidation was unchanged, and safety monitoring revealed that the drug was well tolerated, without an increase in plasma triglycerides. Alopecia occurred in 2 subjects (reversed after stopping the drug), but otherwise no changes were observed in fasting glucose, insulin, ketones, and renal function. Conclusion: These data support the therapeutic potential of a fatty acid synthase inhibitor, TVB‐2640 in particular, in patients with NAFLD and nonalcoholic steatohepatitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.31000

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

Metadata

Authors
Syed‐Abdul, M. M., Parks, E. J., Gaballah, A. H., Bingham, K., Hammoud, G. M., Kemble, G., Buckley, D., McCulloch, W., & Manrique-Acevedo, C.
Venue
Hepatology
Published
2020-05-07
Volume
72
Issue
1
Pages
103-118
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2980950801
Cited by
130
References
11
FWCI
9.11
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.